Evidence map›Paper›PMID 35541738›Full record

ArticleRSC advances2018

Evaluating the efficacy of the anticancer drug cetuximab by atomic force microscopy.

Qingrong Zhang, Yan Shi, Haijiao Xu, Lulu Zhou, Jing Gao, Junguang Jiang, Mingjun Cai, Yuping Shan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Qingrong ZhangSchool of Chemistry and Life Science, Advanced Institute of Materials Science, Changchun University of Technology Changchun 130012 China shanyp@ciac.ac.cn.
Yan ShiChangchun Institute of Applied Chemistry, State Key Laboratory of Electroanalytical Chemistry Chinese Academy of Science Renmin St 5625 Changchun Jilin130022 China caimingjun@ciac.ac.cn.
Haijiao XuChangchun Institute of Applied Chemistry, State Key Laboratory of Electroanalytical Chemistry Chinese Academy of Science Renmin St 5625 Changchun Jilin130022 China caimingjun@ciac.ac.cn.
Lulu ZhouChangchun Institute of Applied Chemistry, State Key Laboratory of Electroanalytical Chemistry Chinese Academy of Science Renmin St 5625 Changchun Jilin130022 China caimingjun@ciac.ac.cn.ORCID https://orcid.org/0000-0002-1029-1038
Jing GaoChangchun Institute of Applied Chemistry, State Key Laboratory of Electroanalytical Chemistry Chinese Academy of Science Renmin St 5625 Changchun Jilin130022 China caimingjun@ciac.ac.cn.ORCID https://orcid.org/0000-0003-0357-570X
Junguang JiangChangchun Institute of Applied Chemistry, State Key Laboratory of Electroanalytical Chemistry Chinese Academy of Science Renmin St 5625 Changchun Jilin130022 China caimingjun@ciac.ac.cn.
Mingjun CaiChangchun Institute of Applied Chemistry, State Key Laboratory of Electroanalytical Chemistry Chinese Academy of Science Renmin St 5625 Changchun Jilin130022 China caimingjun@ciac.ac.cn.ORCID https://orcid.org/0000-0001-5677-5372
Yuping ShanSchool of Chemistry and Life Science, Advanced Institute of Materials Science, Changchun University of Technology Changchun 130012 China shanyp@ciac.ac.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cetuximab is a monoclonal antibody that binds to the epidermal growth factor receptor, which is important in the growth of many cancers. However, the biophysical characteristics of cetuximab as an anti-cancer drug remain elusive. In this study, we adopted atomic force microscopy to measure the mechanical properties of cancer cells following cetuximab treatment and the biomechanical properties of cetuximab and epidermal growth factor receptor interactions. Atomic force microscopy can be implemented as a platform for further investigations that target the cellular stiffness and affinity of ligand-receptor as a therapeutic choice.

Identifiers

PMID35541738
PMCPMC9081852

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.